Skip to content

Medical-device intelligence

QQX: Respiratory Specimen Nucleic Acid Sars-Cov-2 Test

FDA product code QQX: Respiratory Specimen Nucleic Acid Sars-Cov-2 Test. View classification details, related manufacturers, 510(k) clearances, and recall records.

FDA classification ↗

Classification details

Product code
QQX
FDA device name
Respiratory Specimen Nucleic Acid Sars-Cov-2 Test
Device class
2
Regulation number
866.3981
Medical specialty
Microbiology
Review panel
MI

FDA definition

A device to detect and identify nucleic acid targets in respiratory specimens from SARS-CoV-2 that cause COVID-19 is an in vitro diagnostic device intended for the detection and identification of SARS-CoV-2 nucleic acid targets in human clinical respiratory specimens from patients suspected of COVID-19 based on signs and symptoms of respiratory infections by their healthcare providers. The device is intended to aid in the diagnosis of COVID-19 in conjunction with other clinical, epidemiologic, and laboratory data or other risk factors.
Explore microbiology records →
A product code groups records by FDA classification. It does not establish identical intended uses, commercial availability, or comparative device safety.

Record activity in this scope

11 clearance records and 0 recall records in the covered releases, across 7 source company names and 1 product codes. Dated history runs from Nov 1, 2021 to Feb 13, 2025.

Monthly counts through October 2026
Month510(k) decisionsRecall initiations
October 202500
November 202500
December 202500
January 202600
February 202600
March 202600
April 202600
May 202600
June 202600
July 202600
August 202600
September 202600
October 202600

Product codes represented

Code and FDA device nameClearancesRecalls
QQX · Respiratory Specimen Nucleic Acid Sars-Cov-2 Test110

All-history totals use the covered releases; monthly counts stop at the last calendar month covered by both sources. Clearances use decision dates; recalls use initiation dates. 0 records lack the required date and are excluded from monthly counts. These are records, not product launches, market share, incidence rates, or comparative safety. Feed filters below do not change this overview.

Clearances and recall records

11 matching records
Device / recordCompany in FDA recordSourceSource date
Aptima SARS-CoV-2 AssayK243396 · QQXHologic, Inc.510(k)Feb 13, 2025FDA decision date
cobas® SARS-CoV-2 Qualitative for use on the cobas® 5800/6800/8800 SystemsK240867 · QQXRoche Molecular Systems, Inc.510(k)Feb 11, 2025FDA decision date
Xpert® Xpress CoV-2 plus (XPRS-COV2-10)K242109 · QQXCepheid®510(k)Jan 15, 2025FDA decision date
Alinity m SARS-CoV-2 AMP Kit (09N78-096); Alinity m SARS-CoV-2 CTRL Kit (09N78-086)K241580 · QQXAbbott Molecular510(k)Dec 6, 2024FDA decision date
Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR KitK233453 · QQXLife Technologies Corporation510(k)Jul 10, 2024FDA decision date
Xpert® Xpress CoV-2 plusK230440 · QQXCepheid®510(k)Oct 13, 2023FDA decision date
cobas SARS-CoV-2 Qualitative for use on the cobas 5800/6800/8800 SystemsK231306 · QQXRoche Molecular Systems, Inc.510(k)Jun 1, 2023FDA decision date
cobas SARS-CoV-2 Qualitative for use on the cobas 6800/8800 SystemsK213804 · QQXRoche Molecular Systems, Inc.510(k)Oct 22, 2022FDA decision date
Simplexa COVID-19 DirectK212147 · QQXDiasorin Molecular, LLC510(k)Sep 13, 2022FDA decision date
BioFire COVID-19 Test 2K221460 · QQXBiofire Defense, LLC510(k)Jul 25, 2022FDA decision date
BioFire COVID-19 Test 2K211079 · QQXBiofire Defense, LLC510(k)Nov 1, 2021FDA decision date

Manufacturers in these records

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 21, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 21, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗